New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.

The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.

Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.

First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.